An Assessment by the Statin Muscle Safety Task Force: 2014 Update

Statins are among the most consistently beneficial drugs in medicine, and muscle complaints are the single most common reason patients abandon them. This NLA task force report exists to keep a treatable side effect from costing patients a life-saving therapy.

Its first contribution is language. The document standardizes a confusing vocabulary — myalgia, myopathy, myositis, myonecrosis, rhabdomyolysis — so that a vague “my muscles ache” can be sorted into categories with real differences in danger. It offers a Statin Myalgia Clinical Index to gauge how likely a given symptom is actually statin-related, grades muscle injury by creatine kinase elevation, and spells out when a muscle biopsy is warranted.

The most clinically valuable part is the management algorithm, and it carries a hopeful, evidence-based message: most patients who cannot tolerate one statin — somewhere between 72 and 92 percent — can tolerate a different one or an alternative dosing strategy, such as taking a long-acting statin every other day. True, complete statin intolerance is far rarer than the dropout rate suggests.

The honest caveat is that much of this rests on expert consensus and observational data rather than randomized trials, and the index scores are pragmatic tools rather than validated diagnostics.

We rate the evidence strong. Its importance is disproportionate to its modest length: by giving clinicians a structured way to distinguish real statin myopathy from coincidental aches — and a roadmap for getting most patients back on therapy — it protects the benefit of the drugs from being needlessly thrown away.